Scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) have developed a new drug candidate to combat Mycobacterium abscessus, a dangerous infection affecting immunocompromised patients and those with lung diseases. By chemically modifying a widely used antibiotic, the team created a more effective treatment, as reported in Proceedings of the National Academy of Sciences. This breakthrough could save lives by addressing a growing health threat.
The research focused on Mycobacterium abscessus, a pathogen resistant to traditional rifamycin antibiotics, which are typically effective against tuberculosis (TB). The team re-engineered rifabutin to overcome this resistance while minimizing drug interactions, a critical concern for cystic fibrosis patients. Over five years, they tested numerous compounds, identifying two that excelled in laboratory and animal models.
These next-generation rifamycins also show potential against other mycobacterial infections, including Mycobacterium avium complex (MAC) and TB. The rise of M. abscessus infections, particularly among cystic fibrosis patients, underscores the urgency of this work. Recent studies suggest environmental factors, such as mineral-rich water, may contribute to its spread.
Dr. Thomas Dick, a lead author, highlighted the collaborative effort: “This achievement stems from a remarkable partnership across academia and global labs.” The team emphasized the drug’s potential, noting it will advance to clinical development stages. This engineered rifamycin represents a significant advancement in treating M. abscessus and related infections. With further development, it could fill a critical gap in combating antibiotic-resistant pathogens, offering hope for vulnerable patients worldwide.
Add comment